Skip to main content

Lonza moves further into ADCs

Lonza has opened the first of two manufacturing suites at its main site in Visp, Switzerland, for the manufacture of antibody-drug conjugate (ADC) linkers or payloads. This came shortly after an unrelated deal to manufacture antibodies to treat COVID-19 for AstraZeneca and the arrival of a new CEO with a Big Pharma background.

Merck announces ADC/HPAPI expansion

Merck KGaA is to spend €59 million to expand HPAPI and ADC manufacturing capabilities and capacity at its facility near Madison, Wisconsin. Completion is expected by mid-2022 and should add approximately 50 full-time jobs from 2021.

The investment will allow large-scale manufacturing of highly potent oncology compounds, the company said. The 6,500 m2 building will be one of the largest dedicated HPAPI facilities specifically designed to handle single-digit nanogram OEL materials.

Subscribe to ADC